Carrier effects on biological activity of amphotericin B.
Amphotericin B (AmB), the drug of choice for the treatment of most systemic fungal infections, is marketed under the trademark Fungizone, as an AmB-deoxycholate complex suitable for intravenous administration. The association between AmB and deoxycholate is relatively weak; therefore, dissociation o...
Gespeichert in:
| Veröffentlicht in: | Clin Microbiol Rev |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society for Microbiology (ASM)
1996
|
| Schlagworte: | |
| Online-Zugang: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC172908/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8894350/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/cmr.9.4.512 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|